EI
INMB icon

EAM Investors’s INmune Bio INMB Stock Holding History

EAM Investors’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-161,793
Closed -$2.84M – 335
2021
Q2 		$2.84M Buy
+161,793
New +$2.18M 0.44% 59
2020
Q4 		– Sell
-73,734
Closed -$760K – 342
2020
Q3 		$760K Buy
+73,734
New +$750K 0.18% 244

Other funds holding INMB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

EAM Investors's INMB Position: Q3 2021 in Review

EAM Investors sold out of INmune Bio (INMB) in Q3 2021, closing a stake of 161,793 shares — an estimated $2.84M sold.

EAM Investors first reported a position in INMB in Q3 2020 and held it in 2 quarters. The position peaked at $2.84M in Q2 2021. 41 funds tracked by Wall St. Rank hold INMB as of Q3 2021.

  • EAM Investors reported no remaining INmune Bio position as of Q3 2021 after selling out during the quarter.
  • EAM Investors sold 161,793 INmune Bio shares in Q3 2021, an estimated $2.84M.
  • EAM Investors first reported a position in INmune Bio in Q3 2020 and held it in 2 quarters.
  • EAM Investors's INmune Bio position peaked at $2.84M in Q2 2021.
  • 41 funds tracked by Wall St. Rank held INmune Bio as of Q3 2021.

Based on EAM Investors's 13F filing for Q3 2021, filed 12 Nov 2021.